Skip to main content
Midas Edge

Milestone Pharmaceuticals Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

MIST$0.66-10.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Shareholders’ Equity

Condensed Consolidated Statements of Shareholders’ Equit****y (Unaudited)

(in thousands of US dollars, except share data)

​​​​​​​​​​​​​​​​​​​​
​ · ​ · Common Shares · ​ · Pre-funded warrants · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · Numberof shares · Amount · Numberof warrants · Amount · Additionalpaid-incapital · Accumulateddeficit · Total
Balance as of June 30, 2024​53,269,565​$287,932​12,910,590​$53,076​$36,713​$(345,743)​$31,978
Transactions in three-month period ended September 30, 2024​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(9,439)​​(9,439)
Exercise of stock options​—​​—​—​​—​​—​​—​​—
Share-based compensation​—​​—​—​​—​​1,399​​—​​1,399
Employee stock purchase plan purchases​58,343​​74​—​​—​​—​​—​​74
Balance as of September 30, 2024​53,327,908​$288,006​12,910,590​$53,076​$38,112​$(355,182)​$24,012
​​​​​​​​​​​​​​​​​​​​
Balance as of June 30, 2025​53,494,261​$288,263​12,910,590​$53,076​$42,188​$(401,272)​$(17,745)
Transactions in three-month period ended September 30, 2025​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(11,922)​​(11,922)
Exercise of stock options​79,602​​211​—​​—​​(88)​​—​​123
Pre-funded warrants, net of issuance costs​—​​—​3,502,335​​2,573​​—​​—​​2,573
Share-based compensation​—​​—​—​​—​​1,250​​—​​1,250
Issuance of common shares, net of issuance costs​31,500,000​​23,143​—​​—​​—​​—​​23,143
Issuance of Series A common stock warrants, net of issuance costs​—​​—​—​​—​​9,504​​—​​9,504
Issuance of Series B common stock warrants, net of issuance costs​—​​—​—​​—​​13,416​​—​​13,416
Employee stock purchase plan purchases​95,481​​159​—​​—​​—​​—​​159
Balance as of September 30, 2025​85,169,344​$311,776​16,412,925​$55,649​$66,270​$(413,194)​$20,501
​​​​​​​​​​​​​​​​​​​​
Balance as of December 31, 2023​33,483,111​$260,504​9,577,257​$48,459​$33,834​$(326,026)​$16,771
Transactions in nine-month period ended September 30, 2024​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(29,156)​​(29,156)
Exercise of stock options​24,400​​53​—​​—​​(24)​​—​​29
Pre-funded warrants, net of issuance costs​—​​—​3,333,333​​4,617​​—​​—​​4,617
Share-based compensation​—​​—​—​​—​​4,302​​—​​4,302
Issuance of common shares, net of issuance costs​19,666,667​​27,258​—​​—​​—​​—​​27,258
Employee stock purchase plan purchases​153,730​​191​—​​—​​—​​—​​191
Balance as of September 30, 2024​53,327,908​$288,006​12,910,590​$53,076​$38,112​$(355,182)​$24,012
​​​​​​​​​​​​​​​​​​​​
Balance as of December 31, 2024​53,353,984​$288,048​12,910,590​$53,076​$39,568​$(367,545)​$13,147
Transactions in nine-month period ended September 30, 2025​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(45,649)​​(45,649)
Exercise of stock options​109,590​​285​—​​—​​(127)​​—​​158
Pre-funded warrants, net of issuance costs​—​​—​3,502,335​​2,573​​—​​—​​2,573
Share-based compensation​—​​—​—​​—​​3,909​​—​​3,909
Issuance of common shares, net of issuance costs​31,500,000​​23,143​—​​—​​—​​—​​23,143
Issuance of Series A common stock warrants, net of issuance costs​—​​—​—​​—​​9,504​​—​​9,504
Issuance of Series B common stock warrants, net of issuance costs​—​​—​—​​—​​13,416​​—​​13,416
Employee stock purchase plan purchases​205,770​​300​—​​—​​—​​—​​300
Balance as of September 30, 2025​85,169,344​$311,776​16,412,925​$55,649​$66,270​$(413,194)​$20,501
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.